You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 124 No. 6, June 1989 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Angiotropin Treatment Prevents Flap Necrosis and Enhances Dermal Regeneration in Rabbits

Michael Höckel, MD, PhD; John F. Burke, MD

Arch Surg. 1989;124(6):693-698.


Abstract

• Angiotropin is a potent angiogenesis factor isolated from the serum-free media of cultured, lectin-activated peripheral monocytes. In vitro, the purified substance stimulates migration, phenotypic differentiation, and tube formation, but not proliferation of capillary endothelial cells. When injected intradermally, angiotropin induces, in dose-dependent fashion, angiogenesis associated with skin hyperplasia. We have developed a flap model with insufficient blood supply and a model for contraction-free defect healing in rabbit skin. We show that (1) local pretreatment with angiotropin can prevent flap necrosis and (2) dermal regeneration after wounding can be augmented by angiotropin. From these results, we conclude that angiotropin might be of use as an adjuvant to healing in surgery.

(Arch Surg 1989;124:693-698)



Author Affiliations

From the Universitätsfrauenklinik Mainz, West Germany (Dr Höckel), and the Department of Surgery, Harvard Medical School, Massachusetts General Hospital, Boston (Dr Burke).


Footnotes

Accepted for publication July 6, 1988.

Reprint requests to Trauma Services, Bigelow 12, Massachusetts General Hospital, Boston, MA 02114 (Dr Burke).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dual role of macrophages in tumor growth and angiogenesis
Lamagna et al.
J. Leukoc. Biol. 2006;80:705-713.
ABSTRACT | FULL TEXT  

Mechanism of the delay phenomenon: tissue protection is mediated by heme oxygenase-1
Kubulus et al.
Am. J. Physiol. Heart Circ. Physiol. 2004;287:H2332-H2340.
ABSTRACT | FULL TEXT  

Vascular Endothelial Growth Factor-A-Induced Chemotaxis of Monocytes Is Attenuated in Patients With Diabetes Mellitus : A Potential Predictor for the Individual Capacity to Develop Collaterals
Waltenberger et al.
Circulation 2000;102:185-190.
ABSTRACT | FULL TEXT  

Manipulating Angiogenesis: From Basic Science to the Bedside
Pepper
Arterioscler. Thromb. Vasc. Bio. 1997;17:605-619.
ABSTRACT | FULL TEXT  

Effects of Tumor Necrosis Factor {alpha} and Vascular Permeability Factor on Neovascularization of the Rabbit Ear Flap
Stepnick et al.
Arch Otolaryngol Head Neck Surg 1995;121:667-672.
ABSTRACT  

Therapeutic Angiogenesis
Hockel et al.
Arch Surg 1993;128:423-429.
ABSTRACT  

Effects of Endothelial Cell Growth Factor on Vascular Compromised Skin Flaps
Hom and Assefa
Arch Otolaryngol Head Neck Surg 1992;118:624-628.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1989 American Medical Association. All Rights Reserved.